Impact of Fampridine on Upper Limb Function in Multiple Sclerosis
DOI:
https://doi.org/10.25759/spmfr.416Keywords:
4-Aminopyridine, Multiple Sclerosis, Upper ExtremityAbstract
Introduction: Our aim was to assess fampridine impact on upper limbs (UL) function in multiple sclerosis (MS) patients.
Material and Methods: A prospective, unicentric, open-label, non-controlled and non-randomized clinical study in patients diagnosed with MS, EDSS between 4 and 7, clinic with involvement of the upper limbs and under treatment with fampridine. For right (RUL) and left (LUL) upper limbs functional assessment, the 9-Hole-Peg-Test (9-HPT) scale was used immediately before (Pre-RUL and Pre-LUL) and after (Post-RUL and Post-LUL) starting treatment. Statistical analysis was performed using SPSS, with statistical significance set to p<0.05.
Results: From a total of 23 patients, 15 were included. The averages of the time (in seconds) of the evaluations were: pre-RUL 86.12 and post-RUL 50.95; pre-LUL 53.98 and post-LUL 45.08, with statistically significant value for the RUL (p=0.003, dominant upper limb.
Conclusion: The results suggested the potential of fampridine in improving upper limbs function, in addition to the gains already confirmed in gait.
Downloads
References
Kim ES. Fampridine prolonged release: a review in multiple sclerosis patients
with walking disability. Drugs. 2017;77:1593-602.
Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007;68:S22-S54.
Keune PM, Cocks AJ, Young WR, Burschka JM, Hansen S, Hofstadt-van Oy U et al. Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine). BMC Neurol. 2015;15:171. doi: 10.1186/s12883-015-0431-0.
Rodriguez-Leal FA, Haase R, Akgün K, Eisele J, Proschmann U, Schultheiss T, etal.Nonwalkingresponsetofampridineinpatientswithmultiplesclerosis in a real-world setting. Ther Adv Chronic Dis. 2019;10:2040622319835136. doi: 10.1177/2040622319835136
Marion S, Leonid C, Belinda B, Joanne D, Elise H, Leeanne C, et al. Effects of modified-release fampridine on upper limb impairment in patients with Multiple Sclerosis. Mult Scler Relat Disord. 2020;40:101971. doi: 10.1016/j.msard.2020.101971.
Jensen H, Ravnborg M, Mamoei S, Dalgas U, Stenager E. Changes in cognition, arm function and lower body function after slow-release Fampridine treatment. Mult Scler. 2014;20:1872-80.
Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008;71:1134-41. doi: 10.1212/01.wnl.0000326213.89576.0e.
Valet M, Quoilin M, Lejeune T, Stoquart G, Van Pesch V, El Sankari S, et al. Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2019;33:1087-99. doi: 10.1007/s40263-019- 00671-x.
Allart E, Benoit A, Blanchard-Dauphin A, Tiffreau V, Thevenon A, Zephir H, et al. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015;262:1936-45.
Savin Z, Lejbkowicz I, Glass-Marmor L, Lavi I, Rosenblum S, Miller A. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis. J Neurol Sci. 2016;360:102-9.
Pavsic K, Pelicon K, Ledinek AH, Sega S. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clin Neurol Neurosurg. 2015;139:35-40. doi: 10.1016/j.clineuro.2015.08.023.
Lamers I, Kelchtermans S, Baert I, Feys P. Upper limb assessment in multiple sclerosis: a systematic review of outcome measures and their psychometric properties. Arch Phys Med Rehabil. 2014;95:1184-200.
Downloads
Published
How to Cite
Issue
Section
License
Copyright statement
Authors must also submit a copyright statement (as seen below) on article submission.
To the Editor-in-chief of the SPMFR Journal:
The below signed author(s) hereby state that the article
________________________________________ (ref. MFR_________) is
an original unpublished work and all facts stated are a product of the author(s) investigation. This article does not violate any copyright laws or privacy statements. The author(s) also hereby confirm that there is no conflict of interest's issues in this article.
By submitting this article the author(s) agree that after publication all copyrights belong to the SPMFR Journal.
Signed by all authors
Date:
Names (capital letters):
Signatures:
The SPMFR Journal’s contents are follow a Creative Commons licence. After publication the authors can hand out the articles as long as the SPMFR Journal is credited.
